NuSH-Based Therapy
Cross-source consensus on NuSH-Based Therapy from 1 sources and 7 claims.
1 sources · 7 claims
How it works
Benefits
Comparisons
Evidence quality
Highlighted claims
- NuSH-based therapies mimic or enhance hormones released in response to nutrient intake. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- Representative NuSH-based agents include semaglutide, tirzepatide, and retatrutide. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- Their anti-obesity effects involve insulin modulation, delayed gastric emptying, appetite signalling suppression, and adipose tissue lipolysis. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- Clinical trials show substantial weight loss with NuSH-based therapies, but real-world uncertainties remain. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- Semaglutide 2.4 mg once weekly in STEP 1 produced an average 14.9% weight reduction over 68 weeks. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- NuSH-based therapies target regulators including GLP-1, GIP, and glucagon to coordinate appetite, glucose homeostasis, and energy expenditure. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- Tirzepatide 15 mg once weekly for 72 weeks produced weight reductions of up to 20% in adults with obesity. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study